Fredag 22 Maj | 19:04:16 Europe / Stockholm

Svenska | English

Regeneron

Kalender

	Est. tid*
2027-04-29	12:30	Kvartalsrapport 2027-Q1
2027-02-01	N/A	Bokslutskommuniké 2026
2026-10-29	12:30	Kvartalsrapport 2026-Q3
2026-07-31	12:30	Kvartalsrapport 2026-Q2
2026-06-12	N/A	Årsstämma
2026-05-20	-	X-dag kvartalsutdelning REGN 0.94
2026-04-29	-	Kvartalsrapport 2026-Q1
2026-02-20	-	X-dag kvartalsutdelning REGN 0.94
2026-01-30	-	Bokslutskommuniké 2025
2025-11-20	-	X-dag kvartalsutdelning REGN 0.88
2025-10-28	-	Kvartalsrapport 2025-Q3
2025-08-18	-	X-dag kvartalsutdelning REGN 0.88
2025-08-01	-	Kvartalsrapport 2025-Q2
2025-06-13	-	Årsstämma
2025-05-20	-	X-dag kvartalsutdelning REGN 0.88
2025-04-29	-	Kvartalsrapport 2025-Q1
2025-02-20	-	X-dag bonusutdelning REGN 0.88
2025-02-04	-	Bokslutskommuniké 2024
2024-10-31	-	Kvartalsrapport 2024-Q3
2024-08-01	-	Kvartalsrapport 2024-Q2
2024-06-14	-	Årsstämma
2024-05-02	-	Kvartalsrapport 2024-Q1
2024-02-02	-	Bokslutskommuniké 2023
2023-11-02	-	Kvartalsrapport 2023-Q3
2023-08-03	-	Kvartalsrapport 2023-Q2
2023-06-09	-	Årsstämma
2023-05-04	-	Kvartalsrapport 2023-Q1
2023-02-03	-	Bokslutskommuniké 2022
2022-11-03	-	Kvartalsrapport 2022-Q3
2022-08-03	-	Kvartalsrapport 2022-Q2
2022-06-10	-	Årsstämma
2022-05-04	-	Kvartalsrapport 2022-Q1
2022-02-04	-	Bokslutskommuniké 2021
2021-11-04	-	Kvartalsrapport 2021-Q3
2021-08-05	-	Kvartalsrapport 2021-Q2
2021-06-11	-	Årsstämma
2021-05-06	-	Kvartalsrapport 2021-Q1
2021-02-05	-	Bokslutskommuniké 2020
2020-11-05	-	Kvartalsrapport 2020-Q3
2020-08-05	-	Kvartalsrapport 2020-Q2
2020-06-12	-	Årsstämma
2020-05-05	-	Kvartalsrapport 2020-Q1
2019-08-06	-	Kvartalsrapport 2019-Q2
2019-06-14	-	Årsstämma

Beskrivning

Land	USA
Sektor	Hälsovård
Industri	Bioteknik

Regeneron Pharmaceuticals är ett amerikanskt bolag verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling inom allvarliga sjukdomar och vidareutvecklar passande läkemedel. Några av fokusområdena inkluderar exempelvis reumatoid artrit, astma, cancer och diverse infektionssjukdomar. Bolaget grundades år 1988 och har sitt huvudkontor i Eastview, New York.

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2026-05-22 13:00:00 Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

2026-05-21 23:01:52 Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis 643,23 USD | -0,62%

2026-05-18 13:00:00 Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas 628,00 USD | -9,54%

2026-05-16 02:19:44 Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

2026-05-15 20:09:52 Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair 694,25 USD | -3,10%

2026-05-08 13:00:00 Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years 714,16 USD | +0,61%

2026-05-05 13:00:00 Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial 703,07 USD | -0,04%

2026-04-29 12:30:00 Regeneron Reports First Quarter 2026 Financial and Operating Results 676,28 USD | -8,37%

2026-04-23 21:46:16 Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S. 740,00 USD | -0,56%

2026-04-23 18:40:00 Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. 740,00 USD | -0,56%

2026-04-22 23:30:00 Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) 740,00 USD | -0,56%

2026-04-21 16:30:00 Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial 744,67 USD | -0,87%

2026-04-20 22:05:00 Regeneron Announces Investor Conference Presentations 751,17 USD | -0,04%

2026-04-13 12:30:00 Regeneron and Telix Announce Strategic Radiopharma Collaboration 754,63 USD | +1,94%

2026-04-13 07:00:00 Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) 754,63 USD | +1,94%

2026-04-02 22:30:00 Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions 748,53 USD | -3,14%

2026-04-02 18:00:00 EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) 748,53 USD | -3,14%

2026-03-25 21:05:00 Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026 749,26 USD | +1,12%

2026-03-24 07:00:00 Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) 740,98 USD | +0,46%

2026-03-11 02:29:56 Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment 775,68 USD | -0,17%

2026-03-09 12:00:00 Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients 773,79 USD | +2,22%

2026-03-05 22:05:00 Regeneron Announces Investor Conference Presentation 764,66 USD | -2,56%

2026-02-27 13:00:00 Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment 786,00 USD | +2,82%

2026-02-26 18:00:00 Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders 764,47 USD | -2,15%

2026-02-24 15:30:00 Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) 777,17 USD | -1,25%

2026-02-19 13:00:00 Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) 779,90 USD | -1,48%

2026-02-11 22:05:00 Regeneron Announces Investor Conference Presentations 776,45 USD | +1,68%

2026-02-10 13:00:00 Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy 763,64 USD | -1,91%

2026-02-02 13:00:00 EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases 752,31 USD | -0,02%

2026-01-30 12:30:00 Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results 752,46 USD | +0,76%

2026-01-21 18:00:00 Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search 737,67 USD | +1,05%

2026-01-02 22:05:00 Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026 776,55 USD | +0,33%

2025-12-23 07:00:00 Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma 784,37 USD | +0,61%

2025-12-22 22:05:00 Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference 779,63 USD | +1,41%

2025-12-07 22:30:00 Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

2025-11-25 07:00:00 Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) 782,76 USD | +3,23%

2025-11-19 22:10:00 EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications 705,49 USD | -2,13%

2025-11-19 13:00:00 Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation 705,49 USD | -2,13%

2025-11-13 13:00:00 Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs 704,81 USD | +2,76%

2025-11-08 16:46:31 Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

2025-11-07 14:00:00 Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review 648,75 USD | -0,06%

2025-11-03 22:05:00 Regeneron Announces Investor Conference Presentations 632,26 USD | -2,75%

2025-10-31 12:00:00 Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award 650,11 USD | -0,94%

2025-10-28 11:30:00 Regeneron Reports Third Quarter 2025 Financial and Operating Results 644,39 USD | +10,82%

2025-10-17 13:30:19 Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation 577,72 USD | +1,62%

2025-10-15 13:00:41 Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers 579,55 USD | +2,16%

2025-10-12 16:18:30 DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

2025-10-08 20:31:53 Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation 586,30 USD | -0,46%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Regeneron

Kalender

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden